Literature DB >> 17194821

In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Marta Torres-Narbona1, Jesús Guinea, José Martínez-Alarcón, Teresa Peláez, Emilio Bouza.   

Abstract

We evaluated the activities of amphotericin B, itraconazole, voriconazole, caspofungin, and posaconazole against zygomycetes by CLSI M38-A, Etest and Sensititre. The most active drug was posaconazole, followed by amphotericin B and itraconazole. The correlation of the Etest and Sensititre with CLSI M38-A was moderate for posaconazole but poor for the others.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17194821      PMCID： PMC1803125          DOI： 10.1128/AAC.01539-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.

Authors:  A Verma; S Williams; S Trifilio; T Zembower; J Mehta
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

3.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

4.  Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report.

Authors:  A A Cagatay; S S Oncü; S S Calangu; T T Yildirmak; H H Ozsüt; H H Eraksoy
Journal:  BMC Infect Dis       Date:  2001-11-23       Impact factor: 3.090

5.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant.

Authors:  Andrew L Gilman; Amy Serrano; John Skelley; David Zwick
Journal:  Pediatr Blood Cancer       Date:  2006-12       Impact factor: 3.167

7.  Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.

Authors:  P Linden; P Williams; K M Chan
Journal:  Clin Transplant       Date:  2000-08       Impact factor: 2.863

8.  Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis.

Authors:  D P Eisen; J Robson
Journal:  Mycoses       Date:  2004-04       Impact factor: 4.377

9.  Abdominal wall mucormycosis successfully treated with amphotericin and itraconazole.

Authors:  Alan J Hunter; Richard E Bryant
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072

10.  In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Authors:  Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790
View more
  17 in total

1.  Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Authors:  Roxana G Vitale; G Sybren de Hoog; Patrick Schwarz; Eric Dannaoui; Shuwen Deng; Marie Machouart; Kerstin Voigt; Wendy W J van de Sande; Somayeh Dolatabadi; Jacques F Meis; Grit Walther
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.

Authors:  María Guembe; Jesús Guinea; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

4.  Etest cannot be recommended for in vitro susceptibility testing of mucorales.

Authors:  Rita Caramalho; Elisabeth Maurer; Ulrike Binder; Ricardo Araújo; Somayeh Dolatabadi; Cornelia Lass-Flörl; Michaela Lackner
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

5.  Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species.

Authors:  Pauline Vidal; Patrick Schwarz; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 6.  Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.

Authors:  João F Lacerda; Carlos Meneses Oliveira
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

7.  Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

Authors:  Zia U Khan; Suhail Ahmad; Arnost Brazda; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

8.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

9.  High-throughput identification and quantification of Candida species using high resolution derivative melt analysis of panfungal amplicons.

Authors:  Tasneem Mandviwala; Rupali Shinde; Apoorv Kalra; Jack D Sobel; Robert A Akins
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

10.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.